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Introduction
　The abnormality of tumor suppressor gene TP53 has 
been reported in all types of cancer and the mutation is 
recognized in almost 50% of cancers, suggesting that 
the p53 pathway is important in controlling cancer. 
Seventy-ﬁ ve percent of TP53 mutations are missense 
mutations, which deduce one amino acid substitution, 
and result in decreased DNA binding activity and the 
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Abstract : There is no consensus on the relationship between variations in TP53 mutations and tumor prop-
erties in oral squamous cell carcinoma（OSCC）.  To further the basic research required to eventually develop 
individualized（order-made）treatments and prognoses for OSCC, we established six human OSCC lines 
from patients within our department.  Together with another nine cell lines derived from donations by other 
organizations, we determined the TP53 mutation and single nucleotide polymorphism（SNP）of codon 72 in a 
total of 15 cell lines, and examined in vitro cell invasion activity and anti-cancer drug sensitivity.  The mis-
sense mutation at codon 248 was most abundant, and was noted in four cell lines, but other diverse mutation 
variations were also revealed.  The cells which expressed the mutated p53 protein（the p53（＋）group）
showed slightly higher invasion activity than did the p53（－）group.　 In p53（＋）group, the 72R of SNP
（72P/R）was higher than the 72P in invasion activity, although the difference was not signiﬁ cant.  Surpris-
ingly, an anti-cancer drug sensitivity test with four different types of drugs showed that the p53（－）group 
was more resistant in other than CDDP, and that 72R was more sensitive than 72P in the p53（＋）group.  To 
clarify the characteristics of the R248Q mutation, which is the most abundant missense mutation, the gene 
was introduced with an expression plasmid vector into a TP53 null Saos-2 cell.  The transformant of R248Q 
mutation gained higher activity of invasion, while its anti-cancer drug sensitivity also increased.  Our ﬁ ndings 
suggest that it may be possible to estimate oral cancer cell characteristics and the malignancy level based on 
differences in the TP53 mutation.
Key words : Oral squamous cell carcinoma,  p53 Tumor suppressor gene ,  Cell invasion activity,  Anti-canser 
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loss of various functions mediated by the transcription 
of p53 target genes, such as stopping of the cell cycle, 
apoptosis, inhibition of capillary vascularization, and 
DNA restoration.  Consequently, the cells transform 
into malignancies and are involved in immortal conver-
sion, derepression of cell multiplication, and the acqui-
sition of DNA chromosome instability1-3.  This is also re-
lated to other malignant characteristics of cancer cells, 
such as resistance to anti-cancer drugs and radiation, 
cell inﬁ ltration conversion, and increased metastatic ac-
tivity4.
　However, the variations of the missense mutation of 
TP53 are numerous and, by 2004, there were about 
1000 kinds of amino acid substitution reported in the 
literature5-7.  Therefore, it has been suggested that the 
variety of TP53 mutations reﬂ ects the variety of ac-
quired individual cancer properties.  In non-small cell 
carcinoma of lung cancer（NSCLC）and breast cancer, 
TP53 mutations have been reported to be negative prog-
nostic factors of the 5 year survival rate8.  In colon can-
cer and bladder cancer, by contrast, only about half of 
the reports have related the TP53 mutation with the 
prognosis.  For oral cancer, there are too few reports to 
allow an adequate systematic review or meta-analysis. 
Those reports that have dealt with the relationship be-
tween the TP53 mutation and drug sensitivity have 
been contradictory, with some showing positive correla-
tion9-11 and others a negative correlation12-14.  In addi-
tion, not only the mutation of TP53 but also the SNP
（single nucleotide polymorphism）of the 72nd codon 
with an amino acid substitution has been reported.  The 
72P type of CCC codes the proline and the 72R type of 
CGC codes the arginine, and the allele frequency among 
Japanese patients has been reported to be 1.58.  The in-
terpretation differs in nearly every report and for every 
tumor type regarding whether TP53 SNP, or the muta-
tion, affects the carcinogenic sensitivity and prognosis. 
Tada et al.15 reported that the mutated TP53 with 72R 
did not have a dominant negative effect and that, in 
lung cancer, the 72P was associated with a worse prog-
nosis than was the 72R, which was the inverse of the 
ﬁ nding for breast cancer.   In terms of their anti-cancer 
drug sensitivity, the wild type p53 showed more sensi-
tivity than did the mutated p5316，17.  The same group 
reported that the anti-cancer drug sensitivity increased 
when the wild type p53 was introduced into cells pos-
sessing the mutated p5316，17.  However, the clinical ﬁ nd-
ings regarding the relationship between the p53 muta-
tion and anti-cancer drug sensitivity suggest a more 
complex dynamic which involves not simply the type of 
TP53 mutation or SNP of codon 7218, but also other fac-
tors such as the expression of the p53 family member, 
p63 and p7319, the type of anti-cancer drug, and even 
the tissue speciﬁ city or tumor type15.  While it appears 
that the TP53 mutation plays an important function in 
normal cells, is universally mutated in many cancer 
cells, and may be utilized as a diagnostic and prognostic 
factor in some cancers, there is as yet insufﬁ cient data 
to justify more speciﬁ c conclusions given the contradic-
tory ﬁ ndings and confounding variables involved.  In 
the present study, we focused on culturing cells from 
OSCC cases to examine the relationship between cell 
characteristics and the TP53 mutation or polymorphism
（SNP）.
Materials and methods
　This study was conducted with the approval of the 
ethical review board of Tsurumi University.  Informed 
consent was obtained from all of the patients prior to 
this study. 
1. Case, established cell line, transfection, and cell 
culture
　A part of the tissues from the biopsy and excision op-
eration of oral cancer patients who visited the Oral and 
Maxillo-facial Surgery Department from 2002 to 2004 
was cultured in vitro, and the human oral cancer cell 
line was established as follows.
　The tissue was cut ﬁ nely and culture was started in a 
ﬂ ask with Dulbecco’s Modiﬁ ed Eagle Medium（DMEM）
“Nissui”②（Nissui Pharmaceutical Co., Ltd., Tokyo, 
Japan）, 0.2% NaHCO3, L-Glutamine（Nissui Pharma-
ceutical）supplemented with 20% fetal bovine serum
（FBS）under a 37ºC, 5% CO2 atmosphere condition. 
The culture was continued while changing the nutrient 
medium until the out-grown cell from the fragment of 
tissues became conﬂ uent.  Consequently, the cells were 
repeatedly transferred to a new laboratory dish several 
times.  Established cell lines supplied from other orga-
nizations, Japanese Cell Resources Bank（JCRB）or 
American Type Culture Collection（ATCC）, SCC cell 
lines of oral cancer origin, KB, HSC-3, HSC-4, SAS, 
SCC25, Ca9-22, HOC313, HO-1-u-1, HO-1-N-1, a line of 
osteogenic sarcoma origin, Saos-2, and normal ﬁ broblast 
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cell line, TIG-7, were also cultured with it, with the 
DMEM supplemented with 10% FBS.
　The plasmid constructs inserted the mutated TP53 
gene under the CMV promoter ; pCMVneo248Q and 
pCMVneo273H（kindly donated by Professor N. Tsuchi-
da, Tokyo Medical and Dental University）were used 
for the mutated TP53 expression vectors. Two μg of the 
puriﬁ ed plasmids was transfected into 3× 105 cells of 
TP53 null cell line Saos-2 by the DNA-calcium phos-
phate coprecipitation method.  The transformants were 
selected with neomycin analog G418（400 μg/ml）, des-
ignated as Saos248Q and Saos273H or Saos neo as con-
trol which was transfected by only a vector, and were 
cultured with the DMEM supplemented with 10% FBS.
2. cDNA synthesis, ampliﬁ cation, and sequence 
analysis
　From each cell line, total RNA was extracted by 
using the High pure RNA Isolation Kit（Roche Diagnos-
tics Co., Indianapolis, USA）.  The cDNA was synthe-
sized by reverse transcription reaction with Super-
ScriptⅡ Rnase H- Reverse Transcriptase（Invitrogen, 
Carlsbad, CA, USA）.  The full length of the TP53 coding 
region was ampliﬁ ed in each cDNA with p53 speciﬁ c 
primers :  p5312F（5’-acggtgacacgcttccctggattgg-3’）, 
p5312R（5’-tctccacttcttgttccccactgacag-3’）and PfuTur-
bo HotStart DNA polymerase with reaction buffer
（Stratagene, La Jolla, CA, USA）.  The reaction condi-
tions were as follows.  After the ﬁ rst denaturation at 
95℃ for 3 minutes, 35 cycles reaction at 94℃, 1 min., 
60℃, 1 min. and 72℃, 2 min. were performed, and the 
ﬁ nal extension reaction was 72℃, 7 min.  After conﬁ rm-
ing the ampliﬁ cation by agarose gel electrophoresis, the 
PCR product was puriﬁ ed with GFX PCR DNA and Gel 
Band Puriﬁ cation Kit（Amersham Biosciences Corp. 
NJ and USA）, and the sequence reaction was carried 
out with primers  p5312F, p5312R, p53FAS（5’-acacg-
caaatttccttccac-3’）and p53RS（5’-gctgctcagatagcgatg-
gt-3’）, by using ABI Prism BigDye Terminator V3.1 cy-
cle sequencing Kit（Applied Biosystems, Foster City, 
CA, USA）according to the instructions of the manufac-
turer. The base sequence of each reaction product was 
read by the automatic sequencer 3730X DNA analyzer
（Applied Biosystems）.
3. Quantitative real-time PCR
　The equipment used was LightCycler（Roche）and 
LightCycler software Version 3.5（Roche）.  The cDNA 
prepared as described above was used as a template.  As 
for analysis of TP53 gene and GAPDH gene expression 
level, the Quanti Tect Probe PCR Kit（Quiagen, Hilden 
and Germany）and  LightCycler-FastStart DNA master 
SYBR GreenⅠ kit were used with 1 mM of MgCl2.  The 
reaction conditions were as follows.  After the ﬁ rst dena-
turation at 95℃ for 10 min., 45 cycles of reaction at 
95℃, 0 second, 60℃, 5 sec., and 72℃, 15 sec were per-
formed.  The control plasmid DNA pProSp53（supplied 
from the JCRB gene bank）was measured at the same 
time as a standard.  The amounts of expression of the 
GAPDH gene which was the house-keeping gene as an 
internal standard in each cell line, were examined and 
compared. 
4. p53 protein determination by ELISA 
　The cultured cell line was extracted by using Cell Ex-
traction Buffer（Biosource International Inc., USA and 
Camarillo, CA, USA）and used as a sample.  The p53 
protein amounts in each line were determined with the 
ELISA kit of DuoSet IC Human Total p53（R&D Sys-
tems, Minneapolis, MN, USA）according to the manu-
facturer’s instructions and the measurement of the ab-
sorbance with 415 nm（reference wavelength 550 nm）
in an Ultramark microplate reader（BIO-RAD, Rich-
mond, CA, USA）.  The quantity of p53 protein was di-
vided by the total protein amount of each cell to com-
pare the p53 level with each other.  The total protein 
was measured with Protein Assay Kit Ⅰ（BIO-RAD）
based on the Bradford method, according to the manu-
facturer’s instructions.
5. In vitro cell invasion assay
　To evaluate each cell invasion activity, the absorbance 
of extracted chromogen which stained migrated cells 
through the membrane with extracellular matrix was 
measured with the Cell Invasion Assay Kit（Chemicon 
International, Inc., Temecula, CA, USA）20-23.  A statisti-
cal analysis of measurements was performed and p＜
0.05 was judged to be a signiﬁ cant difference in the 
Mann-Whitney U test by using the computer program, 
Stat View-J5.0.
6. Anti-cancer drugs susceptibility test
　The anti-cancer drugs susceptibility was measured by 
MTT（3-［4, 5-dimethylthiazol］-2,5diphenyltetrazolium 
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bromide）assay, essentially as described previously24. 
In short, each cell line was adjusted to the density of 1
× 104 cells/ml, divided into 100 μl per well of a 96-well 
plate（Falcon Becton Dickinson and Co., Franklin 
Lakes, NJ., USA）, and cultured for two hours with the 
DMEM medium supplemented with 10% FBS.  The se-
quential two-fold dilution of the drugs, vincristine sul-
fate（VCR）（Japanese Eli Lili Ltd.）, peplomycin sul-
fate（PEP）（Nippon Kayaku Ltd.）, cisplatin（CDDP）
（Nippon Kayaku Ltd.）, Doxorubicin hydrochloride
（DOX）（Sigma-Aldrich, Tokyo, Japan）of 100 μl was 
added to each well and cultured in the presence of the 
drug for two days.  To the culture, 50 μl of MTT（Thia-
zolyl Blue Tetrazolium Bromide）（Sigma）was added 
and further cultivated for four hours.  After removing 
the culture supernatant, 150 μl of DMSO was added 
into the wells to solve the formazan metabolized from 
MTT and the absorbency of 550 nm（reference wave-
length 630 nm）was measured with an Ultramark mi-
croplate reader（BIO-RAD）.  The experiment in each 
cell line was repeated two to four times independently, 
and the mean value of 50% inhibitory concentration
（IC50）was calculated.  A statistical analysis of data 
was performed and p＜ 0.05 was judged to be a signiﬁ -
cant difference in the Mann-Whitney U test by using 
the computer program, Stat View-J5.0. 
Results
1. The cases and establishing the cell line
　Six cell lines from 81 cases were established in vitro. 
Table 1 shows the characteristics of six cases.  Four pa-
tients were males and two were females ; their average 
age was 58 years old, with a range of 38 to 88 years. 
The original cancer region was the tongue, in four cases, 
the buccal mucosa in one case, and the oral ﬂ oor in one 
case.  Three patients were positive for lymph node me-
tastasis.  The periods from the start of culture to the 
ﬁ rst passage of TOS-1TY was 5 months, TOS-2FY was 3 
months, TOS-3KS was 4 months, TOS-4CO was 3.5 
months, TOS-5MI was 3 months, and of TOS-6AS was 
3.5 months.  Passage continued in each case for about 
12 months.
2. Mutation and SNP analysis of TP53 gene in es-
tablished cell lines
　cDNA obtained from the six novel cell lines we estab-
lished and the nine cell lines obtained from other orga-
nizations was analyzed for the TP53 gene mutation and 
SNP by sequencing.
（1）Mutation analysis
　Mutation of the p53 gene was recognized in most of 
the cell lines（Fig. 1 & Table 2）.
　Most of the mutations were of the missense type.  The 
only cell line without mutations was KB.  HSC-4 had a 
missense mutation on codon 248 changing the arginine 
code to a glutamine code.  HO-1-N-1 and TOS-3KS 
showed the same mutation variation code as HSC-4
（Fig. 1-a）, and in Ca9-22 the missense mutation on co-
don 248 changed arginine code to tryptophan code.  In 
TOS-2FY, 3 bps were deleted which coded phenylala-
nine on codon 113.  In TOS-5MI, glycine code was 
turned into an alanine code by a 1 bp deletion of codon 
105 and consequently, a frame shifted.  In TOS-4CO, 
the serine of codon 94 turned into OPA（Stop codon）
（Fig. 1-b）.  In TOS-1TY, the rearrangement had ap-
peared between codon 281 and the Stop codon.  TOS-
6AS showed re-arrangement from codon 59 to codon 
184.  In HOC313, codon 285 changed the code to lysine 
from glutamic acid.  In HO-1-u-1, there was one base in-
sertion between codon 292-293 to change codon 293 of 
glycine to a tryptophan code, and the following frame 
Table 1　The cases and cell lines established in this study
Cases Sex Age Primary site TNM Stage
Chemotherapy 
before culture
Operation Present status
TOS-1TY
TOS-2FY
TOS-3KS
TOS-4CO
TOS-5MI
TOS-6AS
male
male
female
female
male
male
74
88
38
62
44
41
tongue
buccal mucosa
oral ﬂ oor
tongue
tongue
tongue
T1N0M0
T3N1M0
T3N1M0
T2N2CM0
T1N0M0
T2N0M0
Peplomycin Σ 30mg
―
―
Peplomycin Σ 20mg
Peplomycin Σ 15mg
―
＋
－
＋
＋
＋
＋
Alive
Dead
Dead
Dead
Alive
Alive
Histopathological diagnosis : all cases SCC
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Fig. 1　Data of direct DNA sequencing of the representative cases in Table 2.
（a）Missense of codon 248 revealed by sequence analysis for ampliﬁ ed p53 
cDNA obtained from TOS-3 KS cells and TP53 wild type cells（KB）.
（b）Nonsense of codon 94 revealed by sequence analysis for ampliﬁ ed p53 
cDNA obtained from TOS-4CO cells and TP53 wild type cells（KB）.
Table 2　Analysis of TP53 mutation and SNP of codon 72
Cell lines exon codon Base （amino acid） changing mutation Codon72 SNP
KB
HSC-3 
HSC-4
SAS
SCC25
Ca9-22
HOC313
HO-1-u-1
HO-1-N-1
TOS-1TY
TOS-2FY
TOS-3KS
TOS-4CO
TOS-5MI
TOS-6AS 
8
7
10
4
6
7
8
9
7
8
4
7
4
4
4-5
N.D
305-306
248
336
106
209
248
285
292-293
248
280-
113
248
94
105
59-184
TAAG insertion（frameshift）
CGG（R）→ CAG（Q）
GAG（E）→ TAG（AMB:STOP）
AGC（S）→ ATC（I）
GA deletion（frameshift）
CGG（R）→ TGG（W）
GAG（E）→ AAG（K）
T insertion（frameshift）
CGG（R）→ CAG（Q）
rearrangement
TTC（F）deletion（in-frame truncation）
CGG（R）→ CAG（Q）
TCA（S）→ TGA（OPA:STOP）
G deletion（frameshift）
rearrangement
4bp insertion
missense
nonsense
missense
2bp deletion
missense
missense
1bp insertion
missense
rearrangement
3bp deletion
missense
nonsense
1bp deletion
rearrangement
CCC（P）
CCC（P）
CGC（R）
CGC（R）
CGC（R）
CCC（P）
CCC（P）
CGC（R）
CGC（R）
CGC（R）
CCC（P）
CGC（R）
CGC（R）
CCC（P）
― 
Codon 248 mutations in the DNA binding domain were identiﬁ ed in 4 out of 15 cell lines. 
The genotype of the arginine code（72R）was detected in eight cell lines, and the genotype of the proline code（72P）was de-
tected in six.
The mutations of HSC-3, HSC-4, Ca9-22 and HOC313 were conﬁ rmed in a previous report25.
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was shifted.  In SCC25, the serine code of codon 106 
turned into an isoleucine code, and there after arginins 
was frame-shifted by the deletion of two bases of codon 
209.  In the SAS, the glutaminic acid code of codon 336 
was replaced by Amber（Stop codon）.  The mutations of 
HSC-3, HSC-4, Ca9-22 and HOC313 were conﬁ rmed in 
a previous report25.
（2）SNP on codon 72
　Single nucleotide polymorphism（SNP）has been 
previously reported26 on codon 72 of TP53 gene which 
codes either an arginine or proline.  Eight cell lines 
showed the genotype which coded the arginine（72R）
and six cell lines showed the genotype of proline（72P）
（Table 2）.
3. Expression level of p53mRNA
　The mRNA expression levels of the cell lines were de-
termined by quantitative real-time PCR with cDNA.  A 
standard curve was drawn by using p53 plasmid DNA 
as a standard, and the amount of p53 expression in 
each cell was measured.  The value of the relative ex-
pression was calculated by dividing by the internal 
standard of GAPDH gene expression for comparison 
with a normal ﬁ broblast cell line or with each other.  In 
the novel cell lines, TOS-5MI showed at a low level, and 
it was high in TOS-2FY and TOS-1TY（Fig. 2）.
4. Expression level of p53 protein
　Next, the quantity of expressed p53 protein was mea-
sured using an ELISA in all of the cell lines（except 
TOS-3KS）.  TOS-1TY, TOS-2FY, HSC-4, Ca9-22, 
HOC313 and HO-1-N-1 showed high levels and SAS 
showed an intermediate level in the quantity of p53
（Fig. 3）.  These seven cell lines which showed p53 pro-
tein expression were classiﬁ ed as the p53（＋）group, 
and the others which showed no expression were classi-
ﬁ ed as the p53（－）group.
5. Cell invasion activity
　The invasion activity of each cell line was evaluated 
with the basement membrane model in vitro.  HSC-3 
was measured as a positive control sample because it 
was conﬁ rmed that it caused lung metastasis in a 
mouse model in vivo35.  TOS-2FY, TOS-5MI, HSC-4, 
SAS, SCC25, Ca9-22, HOC313, HO-1-u-1, HO-1-N-1, 
TOS-4CO and TOS-6AS each showed at nearly the 
same level as HSC-3.  The levels of KB and TOS-1TY 
showed signiﬁ cantly lower than that of HSC-3（Fig. 
4-a）.  When the cell invasion activity was compared be-
tween the cell lines with and without the mutated p53 
protein, the p53（＋）group showed slightly higher lev-
els than did the p53（－）group.  Within the p53（＋）
group with the 72SNP, the cell invasion activity in the 
72R type was higher than that in 72P type（Fig. 4-b）.
6. The anti-cancer drug susceptibility
　The anti-cancer drug susceptibility of each cell line 
was determined and compared with the KB cell line, 
which has previously been used to determine the efﬁ ca-
cy of multiple anti-cancer drugs.  Here, we examined 
Fig. 2　Relative level of mRNA determined by quantitative real-time PCR
p53 mRNA levels were divided by internal control of GAPDH mRNA levels, il-
lustrated as relative expression level and compared with normal ﬁ broblast cells.
＊: Normal ﬁ broblast cells from a TOS-1TY host origin. 
In the novel established cell lines, TOS-1TY and TOS-2 FY showed the same 
mRNA level as the normal ﬁ broblast cells of TOS-1TY host origin, and TOS-5MI 
was obviously low.
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the susceptibility against four kinds of anti-cancer 
drugs with different mechanisms of action, and which 
are used frequently.  HSC-4, Ca9-22 and HO-1-u-1 
showed a relatively high IC50 in DOX.  Ca9-22, 
HOC313, HO-1-N-1 and HO-1-u-1 showed a relatively 
high IC50 of CDDP, while TOS-2FY, TOS-5MI and HO-
1-u-1 showed a high IC50 of PEP.  A high IC50 of VCR 
was shown in TOS-2FY and TOS-5MI（Fig. 5a-d-1）.
　The p53（＋）group showed a slightly lower sensitivi-
ty to CDDP, but high sensitivity to DOX, VCR and PEP. 
Within the p53（＋）group, the sensitivity of 72R type 
was apparently higher than that of the 72P, and a sig-
niﬁ cant difference was recognized with type DOX and 
PEP.
7. Examination with a Saos-2 cell with recombi-
nant introduced mutated TP53
　To examine the effect of the mutated TP53 in cells 
with a matched background, mutated TP53 of R248Q 
and R273H was introduced independently into TP53 
null Saos-2 cells, which were designated as Saos 248Q 
and Saos 273H cells, respectively.  The expression of the 
introduced mutated TP53 was conﬁ rmed in both the 
Saos 248Q and Saos 273H cells（Fig. 6a-1,2）.  Saos neo 
introduced with the vector only, and in Saos273H, 
showed that the cell invasion activity was low compared 
with that of HSC-3, but that of Saos 248Q was higher 
than that of Saos neo（Fig. 6）.  Although IC50 of the 
anti-cancer drugs differed according to the drug, 
Saos273H showed a resistant tendency in CDDP, but 
both transformants were obviously susceptible to DOX, 
PEP, and VCR compared to Saos neo. 
Discussion
　In this report, we examined the relationship between 
variation in the TP53 mutation and the characteristics 
of OSCC by using cultured cells.  While we recognized 
that the in vitro culture may not retain all the pheno-
types seen in vivo, it is still of value to culture tumor 
cells in order to examine and better understand the 
functional characteristics of living cells, as is demon-
strated by the many cell biological discoveries that were 
potentiated by the use of cultured cells in cancer re-
search.  In the present study, we sought to establish 
OSCC cell lines from cells derived from OSCC cases 
from our and other facilities, and we successfully identi-
ﬁ ed the TP53 gene mutation in all the strains（except 
KB）established as cell lines.  This suggests the possi-
bility that the cancer cells with TP53 mutations 
were selected for during the establishment.  The TP53 
gene is thought to be an important suicide gene at a 
DNA injury site which eliminates the cell by inducing 
apoptosis.  Therefore, the p53 protein which bears this 
function is not usually detected in normal unstressed 
cells.  However, when the TP53 gene mutates, the mu-
tated p53 protein is excessively produced or accumulat-
ed, thereby compromising apoptosis and leading to ab-
normal or malignant cell growth27.  In our hands, 
however, not all OSCC cells showed overexpression, 
with about half of them lacking this expression（Fig. 3）. 
Fig. 3　Relative level of p53 protein expression per total protein quantity. 
p53 protein per total protein of each cell line was illustrated as a relative expres-
sion quantity and compared with each other. 
＊: Normal ﬁ broblast cells from TOS-1TY host origin.
The relative level of p53 protein was high in TOS-1TY, TOS-2FY, HSC-4, Ca9-22, 
HOC313, and HO-1-N-1.
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（a-1）
（a-2）
Fig. 4　Cell invasion activity
（a-1）A staining image of each cell line which passed a membrane with extracellular matrix and observed to con-
ﬁ rm the evaluation in Fig. 4（a-2）.
（a-2）The eluted strains was measured at OD 560（a-1）
The value was compared with HSC-3 and KB and TOS-1TY were judged to be signiﬁ cantly low. 
（b）A comparison in the presence of the mutated p53 protein expression and codon 72 SNP. 
The p53（＋）group tended to show a slightly high level. The 72R type showed a higher tendency when com-
pared in 72 SNP among the p53（＋）group.
（b）
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（a-1） （a-2）
（b-1） （b-2）
（c-1） （c-2）
（d-1） （d-2）
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In any case, our research should be useful for determin-
ing the relationship between malignancy, drug sensitiv-
ity, and the presence of or deﬁ ciency in the p53 mutant.
　Codons 175, 245, 248, 273, and 282 have been listed 
as hot spots for TP53 gene mutation6.  A codon 248 mu-
tation was found in 4 of 15 cell lines in the present 
study.  Since the area containing this hot spot is consid-
ered part of the core domain（DNA binding domain）
and is thought to be an important region for transcrip-
tion factor functions, the hot-spot mutants of the p53 
protein are likely to at least contribute to abnormal 
transcriptional activity of the target genes as well as to 
cell malignancy.  Although the level of mRNA expres-
sion according to real-time PCR and the amount of the 
p53 protein according to an ELISA were consistent, this 
did not correlate with the observation for KB, TOS-1TY, 
or SCC25（Figs. 2 and 3）.  There was excessive protein 
in TOS-1TY, even though the level of mRNA expression 
was not excessive.  In cancer cells, the pathology seems 
to be related to accumulation because the resolution
（negative feedback）by MDM2 of the mutated p53 pro-
tein is obstructed, and the extended half-life results in 
an excessive expression of the p53 protein28，29.  While 
SCC25 has two kinds of abnormalities in TP53 struc-
ture, repression did not alter the mRNA transcription 
level, although it may function to block the translation 
into protein.  It has been reported in the KB cell line 
that HPV was infected or transformed by the E7 oncop-
rotein, and therefore, that the p53 protein may be easily 
dismantled by the ubiquitin pathway, which accounts 
for the low protein level.  The six cell lines that showed 
protein overexpression all contained the mutation, in-
cluding the missense mutation, a 3 bp deletion that cor-
responded to one amino acid without a frame shift, and 
a rearrangement mutation at the 3’ position.  Regarding 
the overexpression of the mutated p53 protein, we as-
sumed that the increase in malignancy was caused by 
its increase in functions rather than by its deletion, and 
for this reason we investigated the cell invasion activity 
which related to the permeation, expansion, and metas-
tasis of the tumor cells.  We found that the mutated p53
（＋）group had a higher, but nonsigniﬁ cant, tendency 
towards malignancy, which underscored the need for a 
more detailed analysis by mutation type.  However, the 
invasion activity of the positive control cell line, HSC-3, 
was highest among all the cell lines and it was part of 
the p53（－）group（Fig. 4）.  Clearly, cell invasion activ-
ity was affected by factors other than p53 alone.
　Regarding anti-cancer drug sensitivity, some studies 
have reported that the mutated p53（＋）showed low 
sensitivity to most drugs, although it showed a similar8 
or higher sensitivity to drugs that work in microtubule 
polymerization obstruction, such as VCR and Taxol. 
However, these ﬁ ndings may vary by cell type, mutation 
variety, and the study design, and so much more data 
must be collected to better understand these phenome-
na.
　In the TP53 gene, SNP with an amino acid substitu-
Fig. 5　Anti-cancer drug susceptibility
 All tests were compared to the KB cell line as a standard.
（a-1） DOX（Doxorubicin hydrochloride）; 50% inhibitory concentration；IC50 was high in HSC-4, Ca9-22, and HO-1-u-1. 
（a-2） A comparison was made in the presence of the mutated p53 protein expression and 72 SNP 
The susceptibility of the p53（＋）group was higher than the p53（－）group. 
Among the p53（＋）group, the 72R type showed higher susceptibility than the 72P type, and a signiﬁ cant difference was 
recognized between 72R and 72P. 
（b-1） CDDP（Cisplatin）50% inhibitory concentration50；IC50
The mean IC50 of Ca9-22, HOC313, HO-1-N-1 and HO-1-u-1 showed a high level. 
（b-2） A comparison was made in the presence of the mutated p53 protein expression and 72 SNP 
The susceptibility is slightly lower in p53（＋）. 
The 72R type showed a higher susceptibility than the 72P type among the p53（＋）. 
（c-1） PEP（Peplomycin sulfate）50%（inhibitory concentration ; IC50
The mean IC50 of TOS-2FY, TOS-5MI and HO-1-u-1 showed a high level. 
（c-2） A comparison was made in the presence of the mutated p53 protein expression and 72 SNP sensitivity of p53（＋）was 
higher than that of p53（－）. 
The 72R type was higher than the 72P type among the p53（＋）in sensitivity, and a signiﬁ cant difference was recognized. 
（d-1） VCR（Vincristin sulfate）50% inhibitory concentration ; IC50
The mean IC50 of TOS-2FY and TOS-5MI was high. 
（d-2） A comparison was made in the presence of the mutated p53 protein expression and 72 SNP. Sensitivity of p53（＋）was 
higher than that of p53（－）. 
The 72R type was higher than the 72P type among the p53（＋）in sensitivity.
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tion at codon 72 is known36.  It has also been reported 
that an arginine or proline on codon 72 will inﬂ uence 
both of the wild type p53 and the mutated p53.  The 
wild type p53 localizes to the mitochondria and increas-
es the anti-cancer drug sensitivity by inducing apoptosis 
by discharging cytochrome c from the mitochondria to 
the cytoplasm, and this localization has been observed 
strongly for the 72R type of p5330.  While there are vari-
ous reports suggesting a relationship between the ma-
lignant phenotype and the inﬂ uence of codon 72 SNP, 
there is no consensus in the literature31-34.  Thus, we ex-
amined the susceptibility of OSCC lines to four common 
anti-cancer drugs, each of which has a different mecha-
nism of action, and found that the 72R type mutated 
p53 protein was more sensitive to each drug than was 
the 72P type, with signiﬁ cant differences recognized in 
DOX and PEP（Fig. 5）.  However, Sullivan et al.18 
showed that the wild type p53 of the 72R variety was 
more sensitive to cisplatin than was the 72P variety in 
a head and neck SCC cell line, and that the mutated 
p53 showed the inverse of this sensitivity pattern37. 
This phenomenon was thought to indicate that the mu-
tated p53 of the 72R type was bound to the p53 family, 
p73, and inhibits the induction of apoptosis, but it was 
not determined in other drugs than cisplatin.  Thus, 
sensitivity varies not only with the presence of the p53 
mutation, but also with the drug type and the variety of 
the individual mutation.  While the difference was not 
signiﬁ cant, the 72R  variety showed a higher tendency 
towards cell invasion activity.  Further studies should 
investigate the inﬂ uence on cancer control mechanisms 
of the cell invasion activity as a function of the variety
（72P/R）and the TP53 mutation type.
　In our study of these OSCC cell lines, the hottest mu-
tation of TP53 was on codon 248, which is also known to 
show the highest frequency in all cancers in the data-
base5，6 and the next-most frequent mutation was on co-
don 273.  The pathogenicity of these mutations with a 
high frequency is considered to be especially high.  We 
introduced these two TP53 mutations into the p53 null 
Saos-2 cell line independently to clarify the characteris-
tics of the mutations using a ﬁ xed cell background.  The 
sensitivity to anti-cancer drugs of each mutation was 
different as predicted, depending on both the TP53 mu-
tation type and drug type.  The sensitivity of both 
transformants increased a little in DOX and PEP, and 
Saos273H showed a resistance tendency opposite to 
that of CDDP.  The sensitivity of the VCR for both 
transformant types was clearly high.  However, the phe-
notype and the sensitivity probably differ as a function 
of the cell type ; Saos-2 is an osteogenic sarcoma and it 
should be tested on the OSCC cell lines in the same 
manner as we tested.
　In terms of cell invasion activity, the Saos 248Q line 
showed a permeation tendency when compared with the 
control Saos neo, and this was conﬁ rmed in OSCC with 
codon 248 mutated cell lines（HSC-4, Ca9-22, HO-
1-N-1）, and the host of TOS-3KS was also diagnosed as 
N1.  Therefore, it was thought that the 248Q mutation 
of p53 contributed to cell malignancy, although the de-
tailed effects of other mutations must also be consid-
ered.  While it may one day be possible to predict the 
characteristics of OSCC, such as its invasion activity, 
metastasis, and sensitivity to drugs, based on an analy-
Fig. 6　Examination of Saos-2 recombinant.
（a-1） Relative expression level of p53 mRNA 
（a-2） Relative expression level of p53 protein.
The mutated p53 protein expression was conﬁ rmed in Saos 248Q, Saos 273H.
（b） Cell invasion activity was determined by the eluted dye from the cell which migrated through the membrane with extracel-
lular matrix and measuring at OD560.
The value was compared with HSC-3 used as a positive control in Fig. 4.
Saos neo and Saos273H were judged to be signiﬁ cantly low in invasion activity. 
（c） The anti-cancer drug sensitivity was examined, and its 50% inhibitory concentration 50 was calculated as the mean of 
IC50.
（c-1） DOX IC50 value
Saos248Q and Saos273H were a little lower than Saos neo.
（c-2） PEP IC50 value
Saos248Q and Saos273H were a little lower than Saos neo. 
（c-3） VCR IC50 value 
Saos248Q and Saos273H showed high susceptibility. 
（c-4） CDDP IC50 value
Saos273H showed tolerance trend.
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sis of the TP53 mutation and SNP on codon 72, further 
studies that account for a variety of variables will be 
necessary to identify all the relevant factors.
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